National Peroxide Limited (500298) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of National Peroxide Limited ₹206, price ₹621, upside -66.8%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch National Peroxide Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range ₹499.25 – ₹1,991 · fair‑value band ₹59.70 – ₹218.58 · the ₹620.75 price screens above the ₹205.83 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Follow National Peroxide in your weekly email
Every Wednesday you see whether National Peroxide is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
National Peroxide Limited manufactures and sells peroxygens in India. It offers hydrogen peroxide that is used in various industries for chemical synthesis, textile bleaching, paper pulp bleaching, sugar bleaching, non-edible oil bleaching, water and effluent treatment, metallurgy, environmental control, sterilization, and other applications.
Show more
National Peroxide Limited manufactures and sells peroxygens in India. It offers hydrogen peroxide that is used in various industries for chemical synthesis, textile bleaching, paper pulp bleaching, sugar bleaching, non-edible oil bleaching, water and effluent treatment, metallurgy, environmental control, sterilization, and other applications. The company also provides compressed hydrogen gas and per acetic acid; and engages in the investment activities. National Peroxide Limited was founded in 1954 and is headquartered in Mumbai, India.
Stock analysis
National Peroxide Limited (500298) currently trades at ₹620.75, while our model-based Fair Value estimate is ₹205.83, 66.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹337.99 per share, and 0 of the 17 models we run sit above the ₹620.75 price.
Bear case: the Economic Profit group reads lowest at ₹24.78, and 17 of the 17 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹59.70 (bear) to ₹218.58 (bull), the price of ₹620.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Other sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
National Peroxide Limited reported revenue of ₹267M in FY2026 versus ₹2.3B in FY2022, a compound −41.4%/yr. Reported net income was ₹107M in FY2026, compounding +18.5%/yr from FY2022.
Key figures
Market cap ₹11.3B (≈ $117M) · P/E ratio 62.5 · P/S ratio 25.0 · EPS (TTM) ₹31.41 · Dividend yield 0.6% · Net margin 40.0% · Return on equity 1.6% · Return on assets (EBIT) 2.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Other peers we cover trades at 28% fair-value upside, at −67%, 500298 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹10.50 to ₹337.99). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹59.70Fair Value ₹205.83Bull ₹218.58
Price ₹620.75 · Upside -66.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹9.63 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.17/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+36.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−58.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.1%
Start year 2021 (pandemic). Over 10 years: −19.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−9.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.8%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−9.8% vs −12.1%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 41%
Start year 2021 (pandemic)
⚠ Revenue per share shrinking 32.8%/yr over ~7Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare National Peroxide Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Other · 108 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside−66.8% · Bottom 25%
Profitability
Return on equity (TTM)1.6% · Top 25%
Return on assets0.3% · Above median
Net margin (TTM)11.0% · Top 25%
Operating margin (TTM)4.0% · Above median
Growth and dividend
Revenue growth−1.7% · Below median
Dividend yield (TTM)0.6% · Below median
Valuation Multiplesvs Other median · lower = cheaper
P/E (TTM)62.5× · Priciest 25%
P/B1.23× · Pricier than median
P/S (TTM)6.90× · Priciest 25%
EV/EBITDA53.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)0· sector 0
PAST (return on equity)6· sector 0
HEALTH (low debt)100· sector 98
DIVIDEND (yield)13· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is National Peroxide Limited (500298) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹205.83 versus a price of ₹620.75, about −67% upside (overvalued).
What is the fair value of 500298?
Our model-based fair value for National Peroxide Limited is ₹205.83 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹620.75.
What is the quality score of 500298?
National Peroxide Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for National Peroxide Limited (500298)?
Our model-based price target is the fair value of ₹205.83 (as of Oct 2, 2026) from 17 valuation models. Cautious scenario ₹59.70, optimistic scenario ₹218.58. It is a calculation from audited fundamentals, not an analyst target.
What is the National Peroxide Limited stock forecast for 2026?
Our models put fair value at ₹205.83, about −67% upside versus a price of ₹620.75 (overvalued). Cautious scenario ₹59.70, optimistic scenario ₹218.58. The calculation is refreshed regularly with new filings.
Does National Peroxide Limited pay a dividend?
National Peroxide Limited currently shows a dividend yield of about 0.64% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of National Peroxide Limited (500298)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For National Peroxide Limited it is ₹205.83 per share (as of Oct 2, 2026), against a price of ₹620.75. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is National Peroxide Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 500298 trades above its calculated fair value: price ₹620.75, fair value ₹205.83, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 500298?
No. The price is what the market pays today (₹620.75); the fair value is what the company's own numbers justify (₹205.83). For National Peroxide Limited the two are ₹414.92 per share apart. That gap is exactly why we show both numbers side by side.
How much is National Peroxide Limited worth?
The market values National Peroxide Limited at about ₹11.3B (market capitalisation, as of Oct 2, 2026). Per share that is ₹620.75; our models calculate a fair value of ₹205.83 per share.
What do the bullish and bearish scenarios say about 500298?
Our models span a range for National Peroxide Limited: cautious scenario ₹59.70, base ₹205.83, optimistic ₹218.58 per share (as of Oct 2, 2026, price ₹620.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 500298?
National Peroxide Limited trades at a price-to-earnings ratio of 62.5 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹205.83 is built from several models across several years. Other multiples: P/B 1.2, P/S 6.9, EV/EBITDA 53.0.
How solid is the balance sheet of National Peroxide Limited (500298)?
Balance-sheet figures for National Peroxide Limited (as of Oct 2, 2026): return on equity 1.6%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 500298 from its 52-week high?
National Peroxide Limited trades at ₹620.75, about 35% below its 52-week high of ₹961.59 and 24% above the low of ₹499.25 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹205.83 is for.
Which stocks are comparable to National Peroxide Limited?
From the same area (Other) we also value 542772, 532468, 590024, Indiabulls Real Estate Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is National Peroxide Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹620.75, calculated fair value ₹205.83 (−67%), Quality Score 42/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 500298 calculated?
We run National Peroxide Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹205.83, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. National Peroxide Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of National Peroxide Limited (500298)?
The closing price on Oct 1, 2026 was ₹620.75. Our model-based fair value is ₹205.83, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with National Peroxide Limited right now?
The price sits above even our optimistic bull case (₹218.58). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (₹59.70 to ₹218.58). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of National Peroxide Limited
How large is the market capitalisation of National Peroxide Limited (500298)?
The market capitalisation of National Peroxide Limited is ₹11.3B (≈ $117M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of National Peroxide Limited (500298)?
The price-to-sales ratio of National Peroxide Limited is 25.0 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of National Peroxide Limited (500298)?
Earnings per share at National Peroxide Limited are ₹31.41 (price ÷ EPS = P/E 62.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of National Peroxide Limited (500298)?
The dividend yield of National Peroxide Limited is 0.6% (payout 12.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of National Peroxide Limited (500298)?
The net margin of National Peroxide Limited is 40.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of National Peroxide Limited (500298)?
The return on equity (ROE) of National Peroxide Limited is 1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of National Peroxide Limited (500298)?
On an EBIT basis the return on assets of National Peroxide Limited is 2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of National Peroxide Limited (500298)?
The operating margin of National Peroxide Limited is 4.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at National Peroxide Limited (500298)?
Revenue at National Peroxide Limited is growing −1.7% versus a year earlier (3y avg −58.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at National Peroxide Limited (500298)?
Earnings per share at National Peroxide Limited are growing +286% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does National Peroxide Limited (500298) generate?
The free cash flow of National Peroxide Limited is −₹86.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does National Peroxide Limited (500298) carry?
The net debt of National Peroxide Limited is ₹74.6M (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch National Peroxide Limited in the live analysis
One click puts National Peroxide Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
